首页|巴瑞替尼通过JAK2/STAT3通路改善急性肺损伤小鼠肺内皮屏障损伤的研究

巴瑞替尼通过JAK2/STAT3通路改善急性肺损伤小鼠肺内皮屏障损伤的研究

扫码查看
目的 探讨巴瑞替尼通过调节Janus激酶2(JAK2)/信号传导和转录激活因子3(STAT3)通路改善急性肺损伤(ALI)小鼠肺内皮屏障损伤的效果.方法 将雄性C57BL/6小鼠随机分为对照组、模型组和低、中、高剂量实验组.除对照组外,其他4组用腹腔注射脂多糖的方法构建ALI模型.对照组和模型组均灌胃给予等体积0.9%NaCl;高、中、低剂量实验组分别灌胃给予1.00、0.50和0.25 mg.mI.-1巴瑞替尼溶液200 μL.5组小鼠每12 h给药1次,持续给药48 h.用酶联免疫吸附试验法检测支气管肺泡灌洗液中炎症因子的水平,用蛋白质印迹法检测肺组织中紧密连接蛋白(Occludin)、JAK2和STAT3蛋白的表达水平.结果 中、高剂量实验组和模型组、对照组支气管肺泡灌洗液中肿瘤坏死因子-α 分别为(228.48±25.41)、(198.53±23.11)、(317.32±32.85)和(48.93±2.59)ng·L-1,白细胞介素-6 分别为(118.81±14.85)、(98.58±13.82)、(172.23±25.94)和(49.47±3.06)ng·L-1,Occludin 蛋白相对表达水平分别为 0.48±0.13、0.49±0.11、0.28±0.09 和 0.69±0.21,磷酸化JAK2/JAK2 比值分别为 0.51±0.13、0.32±0.09、0.75±0.21 和 0.16±0.05,磷酸化 STAT3/STAT3 比值分别为 0.43±0.11、0.27±0.08、0.78±0.21 和0.17±0.05.中、高剂量实验组和对照组的上述指标与模型组比较,在统计学上差异均有统计学意义(均P<0.05).结论 巴瑞替尼通过抑制JAK2/STAT3信号通路减轻肺部炎症反应,提高肺组织Occludin表达水平,从而保护ALI小鼠.
Study on baritinib improving pulmonary endothelial barrier injury in acute lung injury mice by regulating the JAK2/STAT3 pathway
Objective To explore the effect of barretinib on mice with acute lung injury(ALI)by regulating the Janus kinase 2(JAK2)/signal transducer and activator of transcription 3(STAT3)pathway.Methods The male C57BL/6 mice were randomly divided into control group,model group and experimental-L,-M-H groups.Except for the control group,the other four groups were constructed ALI models by intraperitoneal injection of lipopolysaccharide.The control and model groups were given equal volume 0.9%NaCl by gavage.The experimental-H,-M,-L groups were administered with 1.00,0.50 and 0.25 mg·mL-1 barretinib solution 200 µL by gavage.Five groups were treated for 48 hours with once every 12 hours.The levels of inflammatory cytokine in bronchoalveolar lavage fluid were measured by enzyme linked immunosorbent assay.The expression levels of Occludin,JAK2 and STAT3 in mouse lung tissue were detected by Western blot.Results The levels of tumor necrosis factor-α in bronchoalveolar lavage fluid for experimental-M,-H groups,model group and control group were(228.48±25.41),(198.53±23.11),(317.32±32.85)and(48.93±2.59)ng·L-1;the levels of interleukin-6 were(118.81±14.85),(98.58±13.82),(172.23±25.94)and(49.47±3.06)ng·L-1;the relative expression levels of Occludin were 0.48±0.13,0.49±0.11,0.28±0.09 and 0.69±0.21;the phospho-JAK2/JAK2 ratios were 0.51±0.13,0.32±0.09,0.75±0.21 and 0.16±0.05;the phospho-STAT3/STAT3 ratios were 0.43±0.11,0.27±0.08,0.78±0.21 and 0.17±0.05,respectively.The differences of above indicators were statistically significant between the experimental-M,-H groups,control group and model group(all P<0.05).Conclusion Barretinib can reduce the lung inflammatory response and improves the level of tight junction protein in lung tissue to protect ALI mice by inhibiting the JAK2/STAT3 signaling pathway.

baretinibJanus kinase 2signal transducer and activator of transcription 3acute lung injuryendothelial barrierlipopolysaccharide

王琳、陈军仿、赵保良、王雪莉

展开 >

商丘医学高等专科学校临床医学院,河南商丘 476000

商丘市第四人民医院 儿科,河南商丘 476100

巴瑞替尼 Janus激酶2 信号传导和转录激活因子3 急性肺损伤 内皮屏障 内毒素

河南省高等学校重点科研项目

21B310007

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(16)